Flor, Peter J. and Acher, Francine C. (2012) Orthosteric versus allosteric GPCR activation: The great challenge of group-III mGluRs. BIOCHEMICAL PHARMACOLOGY, 84 (4). pp. 414-424. ISSN 0006-2952,
Full text not available from this repository. (Request a copy)Abstract
Group-III metabotropic glutamate receptors (mGluRs) comprise four structurally related brain and retinal G protein-coupled receptors (GPCRs), mGluR4, mGluR6, mGluR7 and mGluR8, which receive much attention as promising targets for nervous system drugs. In particular, activation of mGluR4 is a major focus for the development of new therapeutics in Parkinson's disease, while mGluR7 activation is considered a potential approach for future treatments of specific psychiatric conditions. The first generation group-III mGluR agonists, e.g. L-AP4 and L-SOP, are characterized by an essential phosphonate functional group, which became a major limitation for the development of systemically active, potent and receptor subtype-selective drugs. Recently however, two approaches emerged in parallel providing resolution to this constraint: in silico high-throughput screening of chemical libraries against a 3D-model of the mGluR4 extracellular domain identified a hit that was optimized into a series of potent and subtype-selective orthosteric agonists with drug-like properties and novel chemotype structures; secondly, high-throughput random screening of chemical libraries against recombinantly expressed group-III receptors identified diverse chemical sets of allosteric agonists and positive modulators, which are drug-like, display selectivity for mGluR4, mGluR7, or mGluR8 and act via novel pharmacological sites. Here, we illustrate new scientific insights obtained via the use of those strategies. Also, we compare advantages and disadvantages of both approaches to identify the desired group-III mGluR activators and we conclude with suggestions how to employ those discovery strategies with success for the identification, optimization, and development of clinical drug candidates; this may have important implications for the entire field of GPCR research. (C) 2012 Elsevier Inc. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | METABOTROPIC GLUTAMATE-RECEPTOR; PARKINSONS-DISEASE TREATMENT; PHARMACOLOGICAL CHARACTERIZATION; RODENT MODELS; IMMATURE RATS; MICE LACKING; IN-VITRO; ACPT-I; NONCOMPETITIVE ANTAGONISTS; ANTICONVULSANT ACTIVITY; GPCR; Metabotropic glutamate; LSP1-2111; LSP4-2022; PHCCC; AMN082 |
| Subjects: | 500 Science > 590 Zoological sciences |
| Divisions: | Biology, Preclinical Medicine > Institut für Zoologie > Molecular and Cellular Neurobiology (Prof. Dr. Peter J. Flor) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 11 May 2020 05:19 |
| Last Modified: | 11 May 2020 05:19 |
| URI: | https://pred.uni-regensburg.de/id/eprint/18295 |
Actions (login required)
 |
View Item |
